[Vascular endothelial growth factor expression and microvessel density in stage I-II non-small cell lung cancer and their prognostic significances].
OBJECTIVE
TNM staging system is used widely to predict prognosis of non-small cell lung carcinoma (NSCLC) patients, but patients with the same stage may have very different survivals; better prognostic index is needed. Angiogenesis is considered to be essential for tumor development, progression, and metastasis, but the prognostic impacts of vascular endothelial growth factor (VEGF) and microvessel density (MVD) in NSCLC is controversial. This study was to evaluate the prognostic value of VEGF and MVD in NSCLC.


METHODS
VEGF and MVD in 214 specimens of stageI-II NSCLC (20 in stage IA, 137 in stage IB, and 57 in stage IIB) were detected by tissue chip and SP immunohistochemistry. No patient underwent postoperative antitumor treatment.


RESULTS
VEGF expression didn't relate to gender, age, blood type, pathologic type, and TNM stage (P0.05). MVD correlated with age and pathologic type (P0.05), but did not relate to gender, blood type, and TNM stage (P0.05). The mean value of MVD was 65.8+/-5.2 in VEGF-low patients, and 67.5+/-2.5 in VEGF-high patients (P0.05). The 5-year survival rate was significantly lower in MVD-high patients than in MVD-low patients (34.5% vs. 60.0%, P=0.013). Furthermore, multivariate Cox regression analysis showed that MVD (P=0.000) was an independent prognostic factor of NSCLC.


CONCLUSIONS
High MVD closely relates to poor prognosis of stageI-II NSCLC.
Zhu
Zhi-Hua
ZH
Department of Thoracic Surgery, Cancer Center, Sun Yat-sen University, Guangzhou, Guangdong, 510060, PR China.
Rong
Tie-Hua
TH
Zeng
Can-Guang
CG
Wu
Qiu-Liang
QL
Ma
Yun
Y
Huang
Xiao-Ping
XP
Li
Bao-Jiang
BJ
Zhang
Peng-Yuan
PY
Zhao
Jin-Ming
JM
Hu
Wei
W
Zhang
Shi-Yi
SY
Yu
Hui
H
Ma
Guo-Wei
GW
Zhang
Lan-Jun
LJ
Wen
Zhe-Sheng
ZS
Fu
Jian-Hua
JH
Long
Hao
H
D000293:Adolescent; D000328:Adult; D000368:Aged; D018952:Antigens, CD34 / Q000378:metabolism; D002289:Carcinoma, Non-Small-Cell Lung / Q000378:metabolism* / Q000473:pathology; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008175:Lung Neoplasms / Q000378:metabolism* / Q000473:pathology; D008297:Male; D008833:Microcirculation / Q000473:pathology; D008875:Middle Aged; D009367:Neoplasm Staging; D011379:Prognosis; D015996:Survival Rate; D042461:Vascular Endothelial Growth Factor A / Q000378:metabolism*
D018952:Antigens, CD34; D042461:Vascular Endothelial Growth Factor A